|
KMID : 1044520200830010014
|
|
Tuberculosis and Respiratory Diseases
2020 Volume.83 No. 1 p.14 ~ p.19
|
|
|
Current Status of Immunotherapy for Lung Cancer and Future Perspectives
|
|
Kim Ho-Cheol
Choi Chang-Min
|
|
|
Abstract
|
|
|
|
Lung cancer remains the most common cause of cancer-related deaths worldwide. Although there are many possible treatments, including targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors, new therapeutic strategies are needed to improve clinical outcomes. Immunotherapy through the use of immune checkpoint inhibitors has provided one of the most important breakthroughs in the management of solid tumors, including lung cancers, and has shown promising results in numerous clinical trials. This review will present the current status of immunotherapy for lung cancer and future perspectives on these treatments.
|
|
|
KEYWORD
|
|
|
Lung Neoplasms, Immunotherapy, Prognosis, Survival
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|